Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Xvivo Perfusion

178.90 SEK

+4.25 %

Less than 1K followers

XVIVO

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+4.25 %
-1.97 %
+9.15 %
-43.39 %
-63.42 %
-62.53 %
-10.10 %
-45.71 %
+841.58 %

Xvivo Perfusion operates in the medical technology industry and focuses on the development and manufacturing of systems for organ transplantation and perfusion. Examples of products that the company supplies include cannulas, organ storage and cooling solutions. The company's products are aimed at healthcare institutions and surgeons. Xvivo Perfusion operates globally, was founded in 1998 and is headquartered in Gothenburg, Sweden.

Read more
Market cap
5.64B SEK
Turnover
23.36M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.1.
2026

Annual report '25

22.4.
2026

Interim report Q1'26

14.7.
2026

Interim report Q2'26

All
Webcasts
Press releases
ShowingAll content types
Press release10/27/2025, 1:29 PM

Redeye: Xvivo Perfusion - And the beat goes on

Xvivo Perfusion
Xvivo, Audiocast, Q3'25
Webcast10/23/2025, 12:00 PM

Xvivo, Audiocast, Q3'25

Xvivo Perfusion
Regulatory press release10/23/2025, 5:30 AM

Interim report January–September 2025

Xvivo Perfusion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release10/20/2025, 12:30 PM

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q3 2025

Xvivo Perfusion
Press release10/13/2025, 5:00 PM

Conference call on Interim Report July-September 2025

Xvivo Perfusion
Press release9/5/2025, 12:30 PM

Nomination Committee of XVIVO Perfusion AB (publ)

Xvivo Perfusion
Regulatory press release7/28/2025, 8:10 PM

Delay in CE approval for XVIVO’s perfusion solution for heart preservation

Xvivo Perfusion
Press release7/21/2025, 7:00 AM

First patient enrolled in US PRESERVE CAP study for XVIVO Heart Assist Transport device

Xvivo Perfusion
Press release7/15/2025, 8:40 AM

Redeye: XVIVO - A major challenge triggers a major opportunity

Xvivo Perfusion
Xvivo, Audiocast, Q2'25
Webcast7/11/2025, 12:00 PM

Xvivo, Audiocast, Q2'25

Xvivo Perfusion
Regulatory press release7/11/2025, 5:30 AM

Interim report January-June 2025

Xvivo Perfusion
Press release7/10/2025, 2:23 PM

Conference call on Interim Report April-June 2025

Xvivo Perfusion
Press release7/8/2025, 2:45 PM

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q2 2025

Xvivo Perfusion
Press release6/13/2025, 11:50 AM

XVIVO honored with 2025 SACC-USA Business Award for life-saving innovation and growth in the U.S. market

Xvivo Perfusion
Press release4/29/2025, 6:00 AM

XVIVO presents 12-month follow-up results from European multicenter heart transplantation trial at ISHLT in Boston

Xvivo Perfusion
Regulatory press release4/25/2025, 12:25 PM

Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)

Xvivo Perfusion
Press release4/25/2025, 7:46 AM

Redeye: XVIVO Update - Temporary growth dip and structural progress

Xvivo Perfusion
Xvivo, Audiocast with teleconference, Q1'25
Webcast4/24/2025, 12:00 PM

Xvivo, Audiocast with teleconference, Q1'25

Xvivo Perfusion
Regulatory press release4/24/2025, 5:30 AM

Interim report January-March 2025

Xvivo Perfusion
Press release4/17/2025, 11:30 AM

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q1 2025

Xvivo Perfusion
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.